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Abstract
Acetylcholine (Ach) has a fundamental role in cortical activation. The activation of
the hippocampus, a cortex implicated in cognitive and sensorimotor functions, is
characterized by an increase in power and frequency of oscillations in the theta (4-10 Hz) and
gamma (30-100 Hz) frequency range. We studied hippocampal activation in two mutant
mouse lines with deficiency in cholinergic functionality: VAChT KDHET (HET), and
VAChTNkx2.1-Cre-flox/flox (KO). We hypothesized that the mutant mice, relative to wild-type
(WT) mice, will manifest abnormal theta and gamma oscillations during different behaviors,
and in response to muscarinic cholinergic antagonist scopolamine hydrochloride and to the
NMDA receptor glutamatergic antagonist CPP. Local field potentials (LFPs) were recorded
from CA1 stratum radiatum in behaving WT and mutant mice before and after injection of
drugs. Immobile theta power decreased in the order of WT, HET, and KO. Injection of
scopolamine abolished the awake-immobility theta in WT and KO mice, but a theta peak
remained in the HET mutant mice. Injection of CPP abolished the awake-immobility theta in
HET mice but not in WT and KO mice. Our data suggests that acetylcholine is critical for
immobile theta power. The presence of a scopolamine-resistant and CPP-sensitive theta
rhythm during awake-immobility in HET mice is a novel finding, since immobilityassociated theta rhythm was found to be scopolamine (or atropine) sensitive in WT mice and
other laboratory animals. The compensatory changes that activate a scopolamine-resistant,
presumably non-cholinergic, theta rhythm during immobility in HET mice remain to be
identified.
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Introduction

1.1 Hippocampus
The hippocampus is part of the limbic system located in the medial temporal lobe
of the human brain and plays important roles in the consolidation of information
from short-term memory to long-term memory and in spatial navigation.

1.1.1 Anatomy and circuitry of hippocampus
The hippocampus is one of the most studied brain areas in part due to its unique
anatomy. The hippocampus in humans has been divided into six segments: dentate gyrus,
cornu amonis (CA1-4) and the subiculum (Amaral and Witter, 1989). In rodents, CA4 is
referred to as dentate hilus (Knowles, 1992). Hippocampal neurons and their projections
have been organized in four layers. Stratum oriens is the most superficial layer followed
by stratum pyramidale, stratum radiatum, and stratum lacunosum-moleculare (Amaral
and Witter, 1989).
Pyramidal cells and granule cells are the two redundant cells found within the
hippocampus. Pyramidal cells are located in cornu amonis regions (CA1, CA2, and
CA3). Granule cells are found in the dentate gyrus, with their cell bodies located within
stratum granulosum and their single dendritic arbour projecting to the molecular layer
(Knowles, 1992). Dentate gyrus receives inputs from entorhinal cortex via the perforant
pathway (Amaral and Witter, 1989; Anderson et al., 1971). Axons of the granule cells
form the mossy fibers and innervate the proximal dendrites of the CA3 pyramidal cells in
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stratum lucidum. Triangular shaped cell bodies of the CA1 pyramidal cells are located in
the stratum pyramidale (Knowles, 1992). Basal and apical dendrites of the CA1
pyramidal cells are located in the stratum oriens and stratum radiatum respectively.
Schaffer collaterals (axons of the CA3 pyramidal cells) innervate both basal and apical
dentrites of CA1 pyramidal cells via commissural and associational paths (Buzaki and
Eidelberg, 1992). Both CA1 and CA3 regions of hippocampus also receive inputs from
enthornial cortex (Amaral and Witter, 1989). Axons of the CA1 pyramidal cells terminate
at subiculum and enthornial cortex.

1.1.2 Interneurons
More than 20 types of interneurons have been classified that mostly use γ–
aminobutyric acid (GABA) as a neurotransmitter (Freund and Buzsaki, 1996; Benes and
Berretta, 2001; Klausberger and Somogyi, 2008). The four main types of interneurons are
bistratified cells, basket cells, chandelier cells, and oriens–lacunosum moleculare (O-LM)
interneurons. Bistratified cells innervate both apical and basal dendritic branches of the
pyramidal cells (Benes and Berretta, 2001). Bistratified interneurons receive input from
CA3 and may participate in generation of CA3-driven gamma oscillation (Tukker et al.,
2007). Basket cells predominantly project to the cell body of pyramidal cells (Benes and
Berretta, 2001). Basket cells burst at theta frequency (4-10Hz), with gamma frequency
(30-100Hz) firing occurring within the bursts (Penttonen et al., 1998). Chandelier cells
(also known as axo-axonic cells) form axo-axonic synapses with the initial segment of
axons and regulate their action potential generation (Benes and Berretta, 2001). The
oriens–lacunosum moleculare (O-LM) interneurons target the apical dendritic tuft aligned
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with the entorhinal cortical input (Klausberger and Somogyi, 2008). Firing rate of
interneurons may change with the behavior of an animal (Ranck, 1973).

1.2 Acetylcholine
Acetylcholine (ACh) in the nervous system has key functions in life, as it
regulates multiple central and peripheral nervous system outputs. Acetylcholine is
synthesized in the cytoplasm from acetyl-coenzyme A (derived from pyruvate generated
in glycolysis within the mitochondria) and choline (Dobransky and Rylett, 2005). The
reaction of choline with acetyl-CoA is catalyzed by an enzyme named choline
acetyltransferase (ChAT) (Dobransky and Rylett, 2005). Synthesized ACh gets stored
within the vesicles via a protein named vesicular acetylcholine transporter (VAChT).
Upon arrival of action potentials, ACh is released into the synaptic cleft by exocytosis
and then it gets degraded via a hydrolytic enzyme named actetylcholinesterase (AChE).

1.2.1 Cholinergic receptors
Muscarinic and nicotinic receptors are the two types of receptors classified for
ACh. Muscarinic receptors are G-protein coupled receptors, and are divided into five
subtypes (M1-M5). A broad range of muscarinic acetylcholine receptors (mAChRs) are
expressed within the hippocampus, with M1, M3 and M5 receptors being mainly
expressed postsynaptically on the pyramidal and granular cells and M2 and M4 receptors
on the interneurons (Levey et al., 1995). M2 receptors also exist presynaptically on the
cholinergic neurons projecting from medial septum to the hippocampus and play an autoregulatory role (Rouse et al., 1999). Activation of mAChRs in the hippocampus
modulates the activity of multiple ligand-gated receptors including N-methyl-D-aspartate
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(NMDA) glutamatergic receptors of the pyramidal cells (Markram and Segal, 1990). In
addition, activation of mAChRs directly excites GABAergic interneurons. At the same
time, it has a depressant effect on the synaptic release of GABA (Cobb and Davis, 2005).
Nicotinic acetylcholine receptors (nAChRs) are made up of a pentametric combination of
α (α2-α10) and ß (ß2-ß4) subunits. In particular, α7 nAChR subtype is highly expressed
in both glutamatergic and GABAergic axon terminals and postsynaptic sites (Fabian-Fine
et al., 2001).

1.2.2 Acetylcholine and long term potentiation
Long term potentiation (LTP) in the hippocampus is proposed to model a
neuronal mechanism of learning and memory formation (Bliss and Collingridge, 1993).
There is evidence that enhancement of septohippocampal cholinergic activity in behaving
mice via stimulation enhances long term potentiation (Galey et al., 1994). The level of
acetylcholine released from terminals varies based on the behavior of the animal (Dudar
et al., 1979). In behaving rats, release of ACh is highest during walking and rapid eye
movement (REM) sleep (Dudar et al., 1979). While the animal is alert-immobile, release
of ACh reduces and the least amount of ACh is released during slow wave sleep (Dudar
et al., 1979). Hippocampal LTP was facilitated when induced during walking, as opposed
to when induced in the absence of theta (i.e. immobility). In addition, systemic
scopolamine or 192 IgG-saporin septal lesions or specific M1 receptor antagonist
pirenzepine attenuated LTP induced during walking without affecting LTP induced
during immobility (Leung et al., 2003).
Ji et al. (2001) reported that activation of presynaptic α7 nAChRs leads to an
enhancement of glutamate release which increases the possibility of inducing LTP. On
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the other hand, activation of α7 nAChRs on hippocampal interneurons can block LTP in
the pyramidal cells (Ji et al., 2001). Activation of septo-hippocapal cholinergic neurons
via optogenetics or electrical stimulation induced different types of hippocampal
Schaeffer collateral to CA1 synaptic plasticity (Gu and Yekel, 2011). Such plasticity
depended on the timing of cholinergic input relative to the Schaeffer collateral input (Gu
and Yekel, 2011). An α7 nAChR-dependent LTP was induced when the cholinergic input
was activated 100 or 10 msec prior to Schaeffer collateral stimulation while the
cholinergic stimulation delayed until 10 msec after the Schaeffer collateral stimulation
induced a mAChR-dependent LTP was induced (Gu and Yekel, 2011).

1.2.3 Alzheimer’s disease and the cholinergic neurons
Alzheimer’s disease (AD) is an age-dependent neurodegenerative disorder
characterized by progressive dementia (Chen et al., 2011). Alzheimer’s disease can be
classified into three stages: 1) an early stage characterized by an inability to remember
novel information where the initial encoding of that information is affected but not the
retrieval of previously learned information; 2) a middle stage where deficits in semantic
memory, working memory, spatial orientation, and attention are especially observed; and
3) a late stage (or dementia) characterized by a global intellectual breakdown associated
with changes in personality and behavior (Bontempi et al., 2001).
It has been hypothesized that cholinergic dysfunction is a major cause for the
cognitive deficit in AD (Bartus et al., 1982).

Synthesis of ACh via choline

acetyltransferase has been found to be decreased in the AD brain (Fisher, 2008). In
addition, presynaptic cholinergic axonal loss can be identified by reduction of vesicular
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acetylcholine transporter (Chen et al., 2011). Degeneration of cholinergic neurons in the
basal forebrain that project to the hippocampus and cerebral cortex is evident in AD
(Fisher, 2008). Using magnetic resonance imaging (MRI) and voxel-based morphometry
(VBM). Teipel et al. (2005) found a positive correlation between stages of AD and
reduction of cholinergic neurons of basal forebrain. This positive correlation may be due
to the interaction between amyloid ß accumulation and cholinergic dysfunction (Schliebs
et al., 2006). The most common prescribed medications to AD patients are the
cholinesterase inhibitors such as Donepezil (Fisher, 2008).

1.3 Glutamate
Glutamate is the most abundant excitatory neurotransmitter in the vertebrate
central nervous system (Meldrum, 2000). Similar to ACh, glutamate must be released
from synaptic vesicles and the transport of glutamate into vesicles is mediated by
vesicular glutamate transporter (VGLUT). To date, three different subtypes of VGLUT
(VGLUT1, 2 and 3) have been identified. VGLUT1 and VGLUT2 are the dominant
isoforms within central nervous system with high level of expression within hippocampus
(Balschun et al., 2010). During early postnatal stages, VGLUT2 expression switches to
VGLUT1 (Myazaki et al., 2003). Several neurological disorders including depression,
Alzheimer’s disease and Parkinson’s disease have been linked to disruption of VGLUT1
and VGLUT2 (Moutsimilli et al., 2005; Kashani et al., 2006; Kirvell et al., 2006).
Tordera et al. (2007) reported that mice with heterozygous knock down of VGLUT1 were
impaired in long-term memory in the novel object recognition task. In another study,
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deletion of VGLUT1 resulted in impaired hippocampal LTP in the CA1 region which
was accompanied by a deficiency in spatial reversal learning (Balschun et al., 2010).
Glutamate receptors are divided into ionotropic and metabotropic receptors.
Metabotropic receptors are indirectly gated G-protein coupled receptors, and ionotropic
receptors are directly gated ion channels. Ionotropic receptors consist of N-methyl-Daspartate (NMDA) and the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
(AMPA) receptor subtypes. NMDA receptors regulate the most common type of LTP in
the CA1 region and dentate gyrus of the hippocampus (Harris et al., 1984; Malenka and
Nicoll, 1993). Ca2+ entry through the NMDA receptor is essential for LTP. Downstream
signaling effects of Ca2+ are believed to be mediated by the α-calcium-calmodulindependent proteinkinase II (CaMKII). While blocking the rise in postsynaptic Ca2+
prevents the induction of LTP, increasing the amount of postsynaptic Ca2+ by photolysis
of caged Ca2+ can mimic LTP (Malenka et al., 1988). Research in behaving rats
confirmed that hippocampal LTP at different synapses has different sensitivity to NMDA
receptor antagonists (Leung and Shen, 1999). Non-NMDA dependent types of LTP have
also been found at the mossy fiber to CA3, and Schaffer collaterals to CA1 (Zalutsky and
Nicoll, 1990; Hanse and Gustafsson, 1994). This type of LTP may be mediated by
voltage-gated Ca2+ channels (Johnston et al., 1992).

1.4 Subcortical inputs to the hippocampus
Neurons of the hippocampus receive inputs from many parts of the brain extrinsic
to the hippocampus. Other than the entorhinal cortex, the major subcortical extrinsic
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inputs to the hippocampus comes from the medial septum (MS) and vertical limb of the
diagonal band of Broca (DBB).

1.4.1 Septohippocampal pathway
Medial septum and diagonal band of Broca (MS-DBB) are parts of the septal
region that project to the hippocampus by four pathways: the fornix, the supracallosal
striae, the fimbria, and the amygdalofugal route (Gaykema et al., 1990). Neurons located
laterally in the medial septum project axons to the medial entorhinal cortex and ventral
hippocampus (Gaykema et al., 1990). Lateral entorhinal cortex and dorsal hippocampus
are innervated by neurons located in the medial portion of the MS and also by afferent
inputs from caudal ventral limb of DBB and medial horizontal limb of DBB (Gaykema et
al., 1990).
Immunohistochemical studies revealed three types of neurons projecting from
MS-DBB to the hippocampus. These neurons were classified as both excitatory and
inhibitory neurons. Cholinergic and glutamatergic neurons are excitatory while
GABAergic neurons are inhibitory (Amaral and Kurz 1985; Manns et al., 2003; Sotty et
al, 2003; Colom et al., 2005; Huh et al. 2010). Furthermore, firing patterns of MS-DBB
neurons were classified based on characteristics such as the maximum firing frequency,
duration

of

the

after-hyperpolarizing

potential,

and

the

prominence

of

a

hyperpolarization-activated current (Griffith et al., 1988; Serafin et al., 1996; Sotty et al.,
2003).
Cholinergic MS-DBB neurons express choline acetyl transferase (ChAT) and are
classified as slow-firing cells (Griffith & Matthews, 1986). Cholinergic neurons are
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mostly located at the caudal and rostral portion of the MS-DBB. Septal cholinergic
neurons innervate both GABAergic interneurons and the principal cells in the
hippocampus (Leranth and Frotscher, 1987). On the other hand, septal GABAergic MSDBB neurons, which express glutamic acid decarboxylase 67 (GAD67) and parvalbumin
(Parv), target inhibitory hippocampal interneurons (Freund and Antal, 1988). Two firing
patterns have been classified for the GABAergic neurons of the MS-DBB: i) fast-firing,
ii) burst-firing (Morris et al., 1999; Knapp et al., 2000; Sotty et al., 2003). The highest
density of GABAergic neurons is located on the middle portion of MS-DBB.
The third type of the MS-DBB neurons are glutamatergic neurons identified
using vesicular glutamate transporter 2 (VGLUT2) (Sotty et al., 2003). These neurons
constitute 4-23% of the projections from MS-DBB to the principal neurons of the CA1,
CA3, and DG of the hippoampus and are distributed evenly within the MS-DBB (Colom
et al., 2005, Huh et al., 2010). Glutamatergic neurons of MS-DBB fire in highly
heterogeneous patterns including: slow-firing, fast-firing, burst-firing and cluster-firing
which is unique to these neurons (Huh et al., 2010). Fast-firing glutamatergic MS-DBB
neurons are the most abundant type with greatest concentration near the midline of the
medial septum similar to the fast-firing GABAergic MS-DBB neurons (Huh et al., 2010).
In addition to innervating the GABAergic and cholinergic neurons in the MS-DBB,
septohippocampal glutamatergic neurons also innervate the inhibitory GABAergic
interneurons and principal neurons in the hippocampus.
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1.4.2 Brainstem to medial septum
Reticularis pontis oralis (RPO) and pedunclulopontine tegmental nucleus (PPT)
are the two structures within the brainstem that provide ascending pathways to the medial
septum (Macadar et al., 1974; Vertes, 1981; Vertes et al., 1993; Oddie et al., 1994).
Neurons of the PPT innervate the supramammillary nucleus (SUM) and the septum while
those ascending from RPO project to the posterior hypothalamic nucleus (PH). A series
of experiments performed by microinfusion of cholinergic agonist carbachol into the
PPT, PRO, SUM, and PH followed by recording LFP from the hippocampus revealed
that majority of the ascending pathways originating from brainstem (PPT and RPO) and
later from hypothalamic nuclei (SUM and PH) are cholinergic and are excitatory (Oddie
et al., 1994). Neurons projecting from SUM to MS-DBB form synapses with both
cholinergic and GABAergic neurons (Borhegyi et al., 1997). Furthermore, SUM also
projects directly to the hippocampus innervating both principal cells (granule and
pyramidal cells) and the GABAergic interneurons (Wyss et al., 1979; Haguland et al.,
1984; Vertes, 1992; Nitsch and Leranth, 1996). In addition to the cholinergic projections
a population of SUM neurons sends glutamatergic afferents to both MS-DBB and
hippocampus (Kiss et al., 2000).

1.5 Hippocampal theta rhythm
The hippocampus produces a sinusoidal-like field potential that occurs at
frequencies 4–10 Hz known as theta rhythm or rhythmical slow-wave activity (RSA). It
has been shown that different neurotransmitters regulate the generation of hippocampal
theta rhythm during different behaviors. Hippocampal theta rhythm is suggested to be
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involved in attention, learning and memory formation, and the integration of motor
programming.

1.5.1 Septal generation of the hippocampal theta rhythm
Medial septum and the vertical limb of the diagonal band of Broca (MS-DBB) are
parts of the septal region that appear to be the most critical system for generating and
maintaining the hippocampal theta oscillations in vivo. Lesion of the MS-DBB resulted
in complete loss of the hippocampal theta rhythm in animals (Green and Arduini, 1954).
Microinfusion of the cholinergic agonist carbachol into the medial septum of both
anesthetized (Oddie et al., 1994) and freely behaving rats (Lawson and Bland, 1993)
induced theta activity in the hippocampus. Intraseptal injection of muscimol, a GABA-A
receptor agonist, abolished the theta rhythm (Oddie et al., 1996). However, intraseptal
injection of 192 IgG-saporin a selective cholinergic neuron toxin in the septum, only
decreased power of theta during walking, but failed to decrease the theta peak frequency
in the behaving rats (Lee et al., 1994). Stimulation of septohippocampal cholinergic
neurons of mice using optogenetics induced theta oscillations in urethane-anesthetized
mice but not in walking mice (Vandecasteele et al., 2014). Optogenetic stimulation of
septal cholinergic neurons significantly suppressed the power of LIA both during
anesthesia and walking (Vandecasteele et al., 2014). Direct application of atropine to the
MS eliminated the atropine-sensitive theta rhythm in the hippocampus in the rat under
urethane anesthesia (Stewart and Fox, 1989). Medial septal injection of NMDA receptor
antagonist decreased the amplitude of the hippocampal theta rhythm but not the
frequency (Leung and Shen, 2004). This suppression of amplitude but not frequency was
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similar to medial septal injection of the GABA-A receptor agonist muscimol (Bland et
al., 1996). The frequency of theta has been suggested to come from the SUM in the
hypothalamus (Kirk et al., 1998).
A model was proposed by Colom (2006) regarding the role of septohippocampal
neurons in generation of the hippocampal theta rhythm. Based on this model, septohippocampal glutamatergic neurons get excited upon activation of septal cholinergic
neurons. Excitation of gluamatergic neurons in conjunction with septal cholinergic cells
provide the necessary excitatory background to initiate the theta frequency oscillations
within hippocampus (Colom et al., 2006). At the same time, both septal cholinergic and
glutamatergic neurons innervate the inhibitory GABAergic interneurons which allow the
septal network to oscillate at theta frequencies (Colom et al., 2006). Rhythmic firing of
the septohippocampal GABAergic neurons leads to rhythmic disinhibition of pyramidal
cells of the hippocampus at the cell body region.
Multiple in-vitro studies have suggested that isolated hippocampus may show an
intrinsic theta oscillation after cholinergic activation (Konopacki et al. 1987).
Administration of a glutamatergic receptor agonist (S)-3,5-dihyroxyphenylglycine
(DHPG), to isolated hippocampal slices induced a high frequency (6-10 Hz) theta rhythm
(Gillies et al., 2002). Intrinsic theta oscillations in single cells are called membrane
potential oscillations (MPOs). Depolarization of single hippocampal neurons, in the
absence of synaptic transmission, is sufficient to induce theta-frequency MPOs,
suggesting that MPOs arise from intrinsic properties of membrane currents (Leung and
Yim, 1991; Leung, 2012). Theta generation from hippocampus itself was also reported in
whole hippocampus preparation in vitro (Goutagny et al., 2009).
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1.5.2 Two types of hippocampal theta rhythm
Vanderwolf first discovered a strong correlation between the moment-to-moment
behavior and hippocampal EEG in behaving rats (Vanderwolf, 1969). Voluntary
movements such as walking, running, and jumping (also known as Type 1 Behavior) and
rapid eye movement (REM) sleep are accompanied by generation of high-frequency (610 Hz) and high-amplitude theta oscillations (Vanderwolf, 1969; Vanderwolf, 1975;
Leung et al., 1982; Oddie and Bland, 1998). Theta rhythm can also be recorded from
animals under anesthesia during electrical stimulation of the brainstem or in response to
sensory stimuli (Stumpf, 1965a; Green, 1964; Bland, 1986; Herreras et al., 1988).
Awake-immobility (also known as Type 2 behavior) with the head held up against
gravity and eyes open is accompanied by generation of a different theta rhythm
(Vanderwolf, 1975). Theta oscillations during this type of behavior have a lower
frequency (4-6 Hz) and are lower amplitude as compared to those recorded during
voluntary movement (Vanderwolf, 1975; Bland and Oddie, 2001). During more
autonomic behaviors including licking, chewing, and shivering and also during
immobility large amplitude irregular activity (LIA) can be recorded in the hippocampus
(Vanderwolf, 1969; Leung et al., 1982; Bland, 1986). Non-REM sleep and anesthesia are
associated with slow oscillations (Wolansky et al., 2006).

The theta rhythm during different behaviors shows different pharmacological
properties, suggesting the participation of different neurotransmitters during different
behaviors (Vanderwolf, 1988; Dudar et al., 1979; Leung et al., 1982; Sainsbury et al.,
1987; Leung 1998; Tai et al., 2011). Administration of cholinergic antagonists abolishes
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the theta rhythm during awake-immobility (also known as Type 2 behaviors). Type 2
behaviors are also referred to as atropine-sensitive (Vanderwolf, 1975; Bland and Oddie,
2001). Furthermore, injection of cholinesterase inhibitors such as eserine induces
atropine-sensitive theta (Bland, 1986). In another study by Tai et al. (2011) a continuous
atropine-sensitive hippocampal theta rhythm was induced by vestibular stimulation
during rotation when rats were immobile. Injection of atropine abolished this rotationinduced theta further demonstrates the role of cholinergic neurons in generation of
hippocampal theta rhythm during Type 2 behaviors (Tai et al., 2011).
Theta rhythm which occurs along with voluntary movements (also known as Type
1 behaviors) is atropine-resistant. Injection of cholinergic antagonist drugs such as
atropine sulphate and scopolamine, even at high doses, fails to abolish the theta rhythm
during Type 1 behaviors. However, it is known that ACh was released in higher level in
the hippocampus during Type 1 than Type 2 behaviors (Dudar et al., 1979), and ACh had
stronger effect on hippocampal electrophysiological responses during walking than
immobility (Leung, 1998). Other than ACh, several neurotransmitters may participate in
the generation of atropine-resistant theta. Vanderwolf (1988) inferred that serotonin (5HT) mediates the atropine-resistant theta rhythm because the combination of centrally
acting atropine and 5-HT depletion in the hippocampus abolished the theta rhythm during
Type 1 behaviors. 5-HT depletion was done by various means, including chemical
depletion, selective lesion of median raphe neurons, sectioning of presumed 5-HT
pathway to the hippocampus (Vanderwolf, 1988). Glutamate NMDA receptors in the
septum and hippocampus may also be part of the atropine-resistant theta (Buzsaki, 2002;
Leung and Desborough, 1988). NMDA receptor antagonist 2-amino-5-phosphonovaleric

15

acid administered in the medial septum or intracerebroventricularly attenuated the
atropine-resistant theta in behaving rats (Leung and Desborough, 1988; Leung and Shen,
2004). Burst firing of the septohippocampal GABAergic neurons driving inhibitory
hippocampal interneurons (Stewart and Fox, 1990) may be yet another component of the
atropine-resistant theta rhythm. Septohippocampal GABAergic neurons are suggested to
be critical for pacing hippocampal theta (Simon et al., 2006; Hangya et al., 2009).
Creation of these two genetically modified lines of mice was another approach to
further prove that two types of theta oscillations co-exist. Shin et al. (2005) provided data
showing that mice lacking phospholipase C (PLC)-ß1 lack one subset of the hippocampal
theta rhythm. (PLC)-ß1 is one of the four PLC- ß isoenzymes that is highly expressed in
the hippocampus within the septohippocampal pathway. Furthermore, PLC- ß1 is coupled
to both muscarinic cholinergic receptors and to group I mGluRs in the hippocampus
(Bland, 1986; Vertes and Kocsis, 1997; Stewart and Fox, 1990; Chuang et al., 2001).
PLC-ß1-/- mice lacked the atropine-sensitive subtype of hippocampal theta rhythm
observed during Type 2 behaviors while the atropine-resistant theta rhythm during Type
1 behaviors was intact (Shin et al., 2005).

1.5.3 Functions of the hippocampal theta rhythm
Synaptic plasticity within the hippocampus can be induced readily by burst
stimulation at a theta frequency (Larson et al., 1986). Other studies showed that induction
of LTP or LTD in the hippocampus depends on the phase of the theta during which
stimulation was applied. Tetanic burst stimulation delivered on the peak of the theta
rhythm recorded during Type 1 behavior induced LTP in stratum radiatum of CA1 region
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of hippocampus; however, stimulation at the trough of the theta induced LTD (Hyman et
al., 2003). The theta rhythm is believed to be important in spatial memory (Winson,
1978). After electrolytic lesion of the medial septum, rats were without a theta rhythm,
and no longer able to perform the spatial tasks (Winson, 1978).
The hippocampal theta rhythm has a critical role in integration of sensory
information and the neuronal processing required for the initiation of voluntary
movements. Vanderwolf (1969) proposed that sensory processing in the hippocampus is
accompanied by generation of the atropine-sensitive theta. Once a voluntary movement
initiates, atropine-sensitive theta co-occurs with the atropine-resistant theta (Bland and
Oddie, 1998). On the other hand, atropine-resistant theta rhythm is an indicator of the
level of activation of motor systems engaged in voluntary movement (Vanderwolf, 1969).
During Type 1 behaviors, frequency of the theta rhythm is linearly related to the speed of
the movement while the amplitude of theta is linearly related with the magnitude of the
movement (Vanderwolf, 1969). In an experiment performed by Bland et al. (2006), rats
were trained to jump to the ledge (height adjustable) of a box in order to avoid shock.
Rats produced atropine-sensitive theta just prior to jump avoidance response. Theta
frequency increased as the height increased while amplitude of theta decreased (Bland et
al. 2006).

1.6 Hippocampal gamma rhythm
Another type of oscillations that can be recorded from the hippocampus is the
relatively high frequency gamma oscillations (30-150 Hz). Hippocampal gamma and
theta rhythms appear to be independently generated (Leung et al., 1982; Leung 1992). In
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the absence of theta rhythm, the power and regularity of gamma oscillation decrease and
a slow irregular pattern of activity appears (Vanderwolf, 1969; Leung et al., 1982).
Entorhinal cortex and the CA3 region of the hippocampus have been identified as the two
independent generators of the hippocampal gamma rhythm (Bragin et al., 1995; Csicsvari
et al., 2003; Colgin et al., 2009).
Using current source density (CSD) analysis, the largest estimated gammaassociated excitatory currents were found in the middle third of the dentate gyrus
molecular layer (Bragin et al., 1995). Medial entorhinal cortex projections terminate in
this zone of dentate gyrus (Bragin et al., 1995). Furthermore, lesions of the entorhinal
cortex caused the gamma-associated excitatory currents to attenuate (Bragin et al., 1995).
The gamma recorded in this region is coherent with excitatory currents recorded from
stratum lacunosum layer of CA1 region which also receives inputs from entorhinal cortex
(Charpak et el., 1995). In the study by Csicsvari et al. (2003), when the CA1 region of the
hippocampus was set as the reference for detecting gamma, excitatory currents emerged
from CA3. Although two gamma oscillators were reported to be usually independent,
they can sometimes couple with each other (Colgin et al., 2009). It has been suggested
that gamma oscillations generated via two different oscillators may produce different
frequency bandwidths (Colgin et al., 2009). Low and high frequency gamma rhythms are
correlated with CA3 and entorhinal cortex projections respectively. Low frequency
gamma (~25-50 Hz) is most abundant during the descending part of the theta rhythm
while high frequency gamma (~65-150 Hz) is maximal close to a theta rhythm trough
(Bragin et al., 1995; Csicsvari et al., 2003; Colgin et al., 2009).
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Many studies have supported the idea that gamma rhythm generation plays a role
in both encoding and retrieval of memories. When human subjects were asked to
remember lists of random words, intracranial recordings revealed an increase of gamma
power during encoding the words that were subsequently recalled (Sederberg et al.,
2007). In another study in behaving rats, it was concluded that high frequency gamma
oscillations recorded from the CA1 region facilitated memory encoding since direct
entorhinal cortex projections to CA1 convey information about the animal’s current
position in environment (Brun et al., 2008; Colgin et al., 2009). On the other hand, the
amplitude of low frequency gamma oscillations originating from CA3 increased as
animals learned to accurately perform a task that involved memory retrieval (Tort et al.,
2009). Both memory retrieval and low frequency gamma rhythm are associated with
increased gamma coherence between CA3 and CA1 while encoding memory and high
frequency gamma are associated with increased gamma coherence between entorhinal
cortex and CA1 region of hippocampus (Charpak et el., 1995; Montgomery and Buzsaki,
2007; Colgin et al. 2009).

1.7 Mice deficient for the vesicular acetylcholine transporter
Vesicular acetylcholine transporter (VAChT) is a twelve-transmembrane domain
protein that stores ACh in synaptic vesicles by means of the electrochemical gradient
produced by a V-type proton ATPase (Roghani et al., 1994). Proper storage of ACh in the
synaptic vesicles via VAChT is necessary for efficient release of ACh from nerve
endings (Parsons, 2000). A reduction of VAChT expression may result in a cholinergic
deficit because of reduction of release of ACh into the synaptic cleft (Chen et al. 2011).
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1.7.1 Heterozygous vesicular acetylcholine knock down mice
Prado et al. (2006) generated a line of genetically modified mice, named VAChT
KDHET, with selective knock down of VAChT gene. These mice were generated by
targeting the 5’ untranslated region of the VAChT gene by homologous recombination in
a mixed 129S6/ SvEvTac (129S6) x C57BL/6J background and were backcrossed to
C57BL/6/Uni for three generations (Prado et al., 2006). Due to altered expression of
VAChT mRNA, these mice had 45% less VAChT protein within their central nervous
system. Despite enhanced intracellular content of ACh (measured by high-performance
liquid chromatography), release of ACh was reduced to almost 33%. Previous studies
revealed that both muscarinic and nicotininc receptors played a role in social memory in
mice (Kampen et al., 2004; Prediger et al, 2006). Consistent with these studies, VAChT
KDHET mice had a significant deficit in social recognition and were clearly impaired in
remembering intruder mice when compared to wild-type mice (Prado et al., 2006).
Similar to certain mouse models of AD (Dewachter et al., 2002) that had object
recognition alterations, VAChT KDHET mice performed worse in object recognition tests
as compared to the wild-type mice (Prado et al., 2006). In another experiment by de
Castro et al. (2009), VAChT KDHET mice were injected with the cholinesterase inhibitor
galantamine in order to clarify whether decreased VAChT levels affect encoding or
retrieval of object recognition memory. Results indicated that increase of the cholinergic
tone facilitated encoding information more effectively (de Castro et al., 2009).

20

1.7.2 Selective basal forebrain VAChT knock out mice
Martin-Silva et al. (2011) introduced a novel genetically modified mouse named
VAChTFloxNeo/FloxNeo (Fig 1B). In order to generate these mice, one LoxP sequence was
placed 260 bp upstream of the VAChT translational initiation codon. A second LoxP was
added approximately 1.5kp downstream from the stop codon immediately followed by
the Neomicin-resistance gene (TK-Neo cassette) which was followed by a third LoxP
(Martin-Silva et al., 2011; Fig 1B). The embryonic stem cells were injected into
C57BL/6J blastocytes to achieve the germ line transmission (Martin-Silva et al., 2011).
Chimeric mice were bred with C57BL/6J mice and heterozygous mice generated (MartinSilva et al., 2011). Finally, VAChTFloxNeo/WT mice were intercrossed and homozygous
VAChTFloxNeo/FloxNeo mice were generated (Martin-Silva et al., 2011; Fig 1B).
VAChTFloxNeo/FloxNeo had a 75% reduction of VAChT mRNA expression in brain. An
increase of 1.4 fold in locomotion in open field was found in VAChTFloxNeo/FloxNeo mice as
compared to wild-type mice (Martin-Silva et al., 2011). The Neo cassette was removed
from VAChTFloxNeo/FloxNeo mice and VAChTFlox/Flox mice was generated.
The Nkx2.1Cre mice were generated in the C57/BL6 strain by pronuclear
injection of linearized bacterial artificial chromosome (BAC) in which fifteen base pairs
at the 5ʹ of exon 2 were replaced with Cre-polyA (Xu et al. 2008; Fig 1A). These mice
were previously used to remove choline acetyltransferase from the forebrain (Patel et al.,
2012). The Nkx2.1Cre mice were crossed with VAChTFlox/Flox mice and VAChTNkx2.1-Creflox/flox

mice were generated which have a selective knock out of VAChT specific to basal
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forebrain including the septohippocampal cholinergic neurons (Al-Onaizi et al., under
review).
A

B

Figure 1 Schematic drawing of generation of Nkx2.1Cre and VAChTFloxNeo/FloxNeo mice.
A) Fifteen base pairs at the 5’ of exon 2, including the ATG, were replaced with CrepolyA (Xu et al., 2008). B) Boxes represent the different exons of ChAT or VAChT. The
position of the initiation codon (ATG) for VAChT and ChAT and the stop codon (Stop)
of VAChT are indicated. Potential transcription initiation sites are indicated for VAChT
(green arrowheads) and ChAT (orange arrowheads). Note that the VAChT gene is within
the first intron of ChAT (Martin-Silva et al. 2011).

1.8 Rationale and hypothesis
In rodents, activation of the hippocampus is manifested by increase in theta (4-10
Hz) and gamma (30-100 Hz) oscillations in the electroencephalogram (EEG).
Acetylcholine (ACh) has a critical role in cortical activation and modulation of cognitive
function and synaptic plasticity (Rasmusson, 2000). The hippocampal theta rhythm
during awake-immobility consists of a cholinergic component (Vanderwolf, 1988;
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Leung, 1998). Disruption of the central ACh function is an early pathology of
Alzheimer’s disease (Francis et al., 1999; Coben, 1985). Mice with heterozygous knock
down of the VAChT gene (VAChT KDHET) showed reduction in release of ACh from
central cholinergic nerve terminals of ~ 33% (Prado et al., 2006). Mice with forebrain
knockout of the VAChT gene (Martyn et al., 2012) had negligible ACh release within
their forebrain. While multiple behavioral deficits were observed in these genetically
modified mice with reduced levels of VAChT, the electrophysiological substrate for these
changes has not been studied. Therefore, whether hippocampal activation is affected in
these two mutant mouse lines is unknown.
We first aimed to record local field potentials (LFPs) from CA1 region (stratum
radiatum) of hippocampus of these two genetically modified lines of mice during walking
and awake-immobility. Their wild-type littermates were used as control. We
hypothesized that mutant mice will manifest hippocampal theta and gamma rhythms
different from control mice. Second, we explored the effect of administration of a
muscarinic cholinergic antagonist drug on hippocampal activation of such genetically
modified mice during different behaviors. We hypothesized that sensitivity of
hippocampal activation of both lines of genetically modified mice to the drug will be
similar to the control mice as their deficiency is in expression of VAChT and not the
muscarinic receptor. Finally, we investigated the role of glutamatergic neurons in
generation of theta and gamma rhythms during different behaviors in these genetically
modified mice by injecting the NMDA receptor antagonist 3-[(R)-2-carboxypiperazin-4yl]-prop-2-enyl-1-phosphonic acid (CPP). We hypothesized that administration of CPP
will cause abnormal hippocampal activation of all mice especially during walking.
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2

Material and methods

2.1 Mutant and control mice
The experiments were performed on two groups of genetically modified. The first
group of mutant mice, named VAChT KDHET, had a heterozygous knock-down of the
vesicular acetylcholine transporter (VAChT) in the brain (Prado et al., 2006). VAChT is
responsible for packaging and release of acetylcholine from synapses. Heterozygous
mutant VAChT mice (VAChT KDHET) were backcrossed with C57BL/6J animals for
three generations (Prado et al. 2006). Three of their wild-type littermates were used as
control mice.
The second group of mice, named VAChTNkx2.1-Cre-flox/flox(+,+), had VAChT
deletion restricted to the forebrain, by crossing Nkx2.1-Cre mouse line (C57BL/6JTg(Nkx2-1- cre)2Sand/J), with VAChTflox/flox mice (crossed for 5 generations with
C57BL/6J) (Al-Onaizi et al., under review). Three of the VAChTNkx2.1-Cre-flox/flox(+,+) mice
littermates were used as control mice. These control mice had the LoxP however
expression of VAChT was not affected and they were named VAChTNkx2.1-Cre-flox/flox(-,-).
Hereafter, control mice including both wild-type and VAChTNkx2.1-Cre-flox/flox(-,-)
mice will be referred to as WT (Wild-Type) mice, VAChT KDHET will be referred to as
HET (Heterozygous) mice and VAChTNkx2.1-Cre-flox/flox(+,+) mice will be referred to as KO
(Knock Out) mice. Mice were housed in groups of 3 to 4 in each cage, with food and
water available ad libitum. Temperature of the room was maintained at 22°C ± 1 with
with a 12/12 h light/dark cycle beginning at 7 a.m. All surgical and experimental
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procedures were approved by the Animal Use Subcommittee of the University of
Western Ontario Council on Animal Care, in accordance with Canadian Council of
Animal Care policy.

2.2

Electrode implantation
The experiments were conducted on 18 adult male mice 6 HET mice, 6 KO mice,

and 6 WT mice (3 of which were littermates of HET mice and the other 3 littermates of
KO mice) weighing 28-54 g. Animals were anesthetized with ketamine (100 mg/kg) and
xylazine (25 mg/kg) in 0.9% saline (intraperitoneal, i.p.). During the surgery, anesthetic
condition of the animal was tested every 20 minutes by toe pinching and a supplementary
dose was injected if needed. The head of the animal was fixed on to a stereotaxic frame
using blunt ear bars and the skull was adjusted to fit the lambda and bregma in the same
horizontal plane. Throughout the implantation, body temperature was maintained
between 35-37°C using a rectal thermometer. The skull was exposed and two small holes
were drilled bilaterally over the hippocampal CA1 region (AP -2.3 mm, L ± 1.6 mm)
based on the coordinates of the mouse brain atlas (Franklin and Paxinos 1998). An
electrode comprised of a 125-µm Teflon-insulated stainless steel wire recording from one
cut end, and soldered to a female miniature connector at the other end. Two electrodes
were bundled together for placement in the CA1 region of the hippocampus with the deep
electrode targeting the stratum radiatum and the shallow one targeting the alveus. A small
hole was drilled over the left cerebellum and another one drilled over the right frontal
cortex. A jeweller’s screw was placed over each of these holes and served as a recording
ground. Next, a thin layer of cyanoacrylate (Krazy Glue) was applied over the skull.
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Finally, electrodes and screws were fixed using dental cement. In order to avoid loss of
the head cap, mice were housed individually in a large cage (25cm x 40cm x 15cm) after
the implantation.

2.3

Recording and analysis
The mice were allowed 4-6 days to recover from surgery. Later, a cable was

connected to the electrodes via the female miniature connector pins on the head cap. A
mouse was placed in a cubic plastic cage (30 cm x 30 cm x 30 cm) and allowed to
habituate for 10 minutes to the recording environment. Hippocampal LFP was recorded
from the freely behaving mouse during periods of awake-immobility and walking. The
behavior of the mouse was visually monitored and annotated during the recording of
LFP. A mouse was considered to be awake-immobile when it was motionless in an alert
state with its head held up against gravity and eyes open. Ear flicks, eye blinks and
movement of nostril during immobility were also included as part of the awakeimmobility behavior. Besides the regular walking, other behaviors including running,
rearing, turning, digging and postural movements were also considered as walking
behavior. Hippocampal LFP was recorded for 30-45 minutes (each record was 60
seconds long) from the mouse as a baseline condition. Then, 5 mg/kg i.p. scopolamine
hydrochloride (muscarinic cholinergic antagonist) was injected (i.p.), and LFP recordings
stated 10 minutes after injection for another 30-45 minutes. A week after the first
recording, mice were experimented again under the same procedure however during the
second recording instead of scopolamine a 10 mg/kg i.p. dose of NMDA receptor
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antagonist CPP (3-[(R)-2-carboxypiperazin-4-yl]-prop-2-enyl-1-phosphonic acid) was
injected.
The power spectrum was constructed from averaging at least 15 segments LFP of
each behavior (awake-immobility or walking), either for baseline or after injection of a
drug. Segments of the LFP recordings were selected manually in order to eliminate any
artifacts. Each segment was 1024 points or 5.12 s with 200 Hz sampling (Leung et al.,
1982). Six average power spectra were plotted for each mouse, for the following
condition: i) awake-immobility, ii) scopolamine awake-immobility, iii) CPP awakeimmobility, iv) baseline walking, v) scopolamine walking and vi) CPP walking. Each
spectrum had a frequency resolution of 0.19 Hz (1/5.12 s), and elliptical smoothing over
5 bins made statistically independent values were separated by 5 bins, or 0.95 Hz, but
with more than 150 degrees of freedom. Power spectra were plotted in arbitrary
logarithmic units, with the calibration of 5.43 log units = 1 mV peak-to-peak amplitude
of a sine wave. An increase of 1 logarithmic power unit signified a 10-fold increase in the
squared amplitude of the LFP at a specific frequency.

2.4 Histology
At the end of experiments, mice were deeply anesthetized with 30% urethane and
perfused through the heart with 100 ml of cold saline followed by 100 ml of cold 4%
formaldehyde. The brain was extracted from the cranium and placed in 4% formaldehyde
solution until ready for sectioning. Coronal brain sections of 40 µm thick were cut using
a freezing microtome and mounted on slides and stained with thionin. Electrode

27

microscope Photos
placements were verified by 100X magnification of the slides using a microscope.
were taken from brain sections using a digital camera.

Figure 2 Top: Hippocampal
ippocampal CA1 region (AP -2.3
2.3 mm, L ± 1.6 mm) based on the
coordinates of the mouse brain atlas (Franklin and Paxinos 1998) Bottom: Coronal brain
sections (left
left and right side) stained with thionin. Electrode placements (red arrows) were
verified by magnification of the slides using a microscope.
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2.5 Statistical analysis
Four measures were obtained from each power spectrum derived from a single
mouse: i) theta peak frequency (3-10 Hz), ii) theta peak rise (logarithmic units), iii)
average logarithmic power of low gamma frequency (30-58 Hz) and iv) average
logarithmic power of the high gamma frequency (62-100 Hz). The theta peak rise is the
difference between the power (in logarithmic units) at the theta peak (maximum) and the
power of the valley (minimum) immediately before the theta peak. Theta peak rise gives
an indication of the power of the rhythmic oscillations at the theta frequency. All data
were expressed as mean ± standard error of the mean (SEM) when applicable. All
statistics were performed using the GraphPad Prism 5.0 software. Each of the 4 variables
introduced above was subjected to several two-way Analysis of Variance (ANOVA) or
paired t-tests. The groups of mice (WT, HET and KO) was set as a between factor and
behavior (walking/awake-immobility) was set as a within factor. In some of the two-way
ANOVAs performed, effect of the drug (scopolamine hydrochloride/CPP) on any of the
above variables was set as the within factor rather than the behavior. Statistical
significance was set at P < 0.05.
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3

Results

3.1 Baseline LFP recording during awake-immobility and
walking
Local field potentials (LFPs) were recorded from CA1 region of hippocampus of
18 adult male mice (6 Wild-Type mice (WT), 6 VAChT KDHET mice (HET), and 6
VAChTNkx2.1-Cre-flox/flox mice (KO)). Mice were placed in a cubic cage (30 cm x 30 cm x
30 cm) and allowed ten minutes to habituate. LFPs were recorded for 30-45 minutes
while mice were freely behaving. Three of the control mice were wild-type littermates of
the HET mice and the other three were VAChTNkx2.1-Cre-flox/flox(-,-) mice. No significant
difference was seen in case of any of the experimental results (theta peak frequency and
power, low- and high-frequency gamma power, and response to drugs) between these two
control groups (paired t-tests and 2-way ANOVAs, n = 3, P > 0.05) thus we considered
them all as WT mice.
During awake-immobility, the frequency of theta rhythm was stable at ~ 5 Hz as
indicated by time-frequency spectrogram (Fig. 3B) and the LFPs (Fig. 3C). During
awake-immobility, the average theta rhythm peak frequency recorded from 6 WT mice
was 4.47 ± 0.21 Hz (Fig. 6-7), with a rise of theta peak of 0.53 ± 0.03 log unit (Fig. 6-7).
Theta peak frequency increased to about 8 Hz during walking, as shown by the LFPs and
spectrogram of a representative mouse (Fig. 3B, C). As a group, theta frequency in WT
mice was higher during walking as compared to awake-immobility (7.77 ± 0.15 Hz, n =
6, paired t-test, P < 0.001; Fig. 7). WT mice manifested significantly higher theta power
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Figure 3 Hippocampal activation of a representative wild-type (WT) mouse. A)
Representative LFP traces recorded from CA1 stratum radiatum of a WT mouse during
awake-immobility (top) and walking (bottom). B) Time-frequency spectrogram indicates
relatively stable theta frequency during 60 sec of recording (horizontal axis); the vertical
axis represents frequency from 0 to 100 Hz, with color (red: strong, blue: weak) intensity
calibration in power (dB). 20 dB is equal to 1 log power unit. C) Power spectra of
hippocampal LFPs during awake-immobility (blue trace) and walking (red trace). Theta
rhythm during awake-immobility was lower in frequency and amplitude as compared to
the same measure recorded during walking. Gamma power at 50-100 Hz was higher
during walking than awake-immobility.
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during walking as compared to awake-immobility (0.86 ± 0.07 log units, n = 6, paired ttest, P < 0.001; Fig. 7). Low-frequency (30-58 Hz) gamma power did not change
significantly with behavior (awake-immobility: 2.40 ± 0.09 log units, walking: 2.55 ±
0.09 log units, n = 6), as confirmed by paired t-test P > 0.05; Fig. 7). However, highfrequency (62-100 Hz) gamma power was significantly larger during walking as
compared to awake-immobility (awake-immobility: 1.85 ± 0.09 log units, walking: 2.12
± 0.12 log units, n = 6), as shown by paired t-test P < 0.001; Fig. 7).
Theta peak frequency of HET mice during awake-immobility and walking was
4.92 ± 0.03 Hz and 8.34 ± 0.15 Hz, respectively (n = 6; Fig. 6-7). HET mice showed a
significantly higher theta power during walking (0.89 ± 0.04 log units) as compared to
awake-immobility (0.40 ± 0.02 log units, n = 6, paired t-test, P < 0.0001; Fig. 6). Both
low- and high- frequency gamma power were significantly stronger during walking as
compared to awake-immobility (n = 6, paired t-test, P < 0.01; Fig. 6). The average
logarithmic power of low-frequency gamma oscillations of 6 HET mice was 2.60 ± 0.15
log units during awake-immobility and 2.79 ± 0.08 log units during walking (Fig. 6).
Higher theta frequencies were found in HET mice as compared to WT mice at a
fixed behavior (Fig. 7); the difference was statistically significant during walking (2-way
ANOVA group effect, F

(1, 10)

= 12.87, P < 0.05) but not during awake-immobility.

During awake-immobility, the theta power in HET mice was lower than that in WT mice
(2-way ANOVA group effect F

(1, 10)

= 60.29, P < 0.05; Fig. 7). Results of a 2-way

ANOVA (group x behavior) revealed that between WT and HET mice, there was no
significant difference in the power of low-frequency gamma rhythm during either of the
behaviors (F (1, 10) = 0.07, P = 0.80; Fig. 7). Similar results were obtained for high

32

VA C h T K D (H E T ) M o u s e
A

A w ake-Im m o b ility

1 m V

W a lkin g

1

s e c

B

Awake-Im m obility

Walking

7 0

Frequency (Hz)

1 0 0

6 0

9 0

5 0

8 0

4 0

7 0
3 0

6 0

2 0

5 0

1 0

4 0
3 0

0

2 0

-1 0

1 0

-2 0

0

-3 0
0

1 0

2 0

3 0

4 0

5 0

6 0

0

Tim e (sec)

1 0

2 0

3 0

4 0

6 0

Tim e (sec)

5

C

5 0

Power
(dB)

Immobile No Drug
Walking No Drug

Log Power

4
3
2
1
0
0

10

20

30

40

50

60

70

80

90

100

F re q u e n c y (H z )

Figure 4 Hippocamapal activation of a representative VAChT KDHET mouse. A) LFP
traces recorded from the CA1 region of the hippocampus of a HET mouse during awakeimmobility (top) and walking (bottom). B) Time-frequency spectrogram indicates stable
theta frequency during 60 sec of recording, and the higher gamma power during walking
than immobility. C) Power spectra during awake-immobility (blue trace) and walking
(red trace). Theta rhythm during awake-immobility was lower in frequency and
amplitude as compared to the same measure recorded during walking. Power of gamma is
significantly higher during walking.
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frequency gamma oscillations (2-way ANOVA group effect, F (1, 10) = 0.01, P = 0.91; Fig.
7).
Walking in KO mice was accompanied by significantly higher theta power (0.93
± 0.03 log unit) and higher peak frequency theta rhythm (7.83 ± 0.20 Hz, n = 6, paired ttest, P < 0.001; Fig. 6) as compared to the same measure during awake-immobility (3.81
± 0.19 Hz, 0.09 ± 0.02 log unit). Power of the low-frequency gamma in KO mice
increased significantly during walking (2.86 ± 0.12 log units) as compared to awakeimmobility (2.55 ± 0.13 log units, n = 6, paired t-test, P < 0.001; Fig. 6). Similar results
were observed for high-frequency gamma power (awake-immobility: 1.76 ± 0.11 log
units, walking: 2.07 ± 0.11 log unit, n = 6, paired t-test, P < 0.05; Fig. 6).
Compared with WT mice, KO mice manifested a significantly lower theta peak
frequency during awake-immobility (2-way ANOVA group factor, F (1,

10)

= 4.65, P <

0.05; Fig. 7). Furthermore, awake-immobility theta showed significantly lower power in
KO mice than in WT mice (2-way ANOVA group factor, F (1, 10) = 55.82, P < 0.001; Fig.
7). No significant difference in theta peak frequency was observed between WT (7.77 ±
0.15 Hz) and KO mice (7.83 ± 0.20 Hz) during walking (2-way ANOVA group factor, F
(1, 10)

=0.05, P = 0.83; Fig. 7). Also, there was no significant difference in the walking

theta power between WT (0.86 ± 0.07 log unit) and KO mice (0.93 ± 0.03 log unit) (2way ANOVA group factor, F (1, 10) = 0.06, P = 0.82; Fig. 7).

34

VA C h T
A

N k x 2 .1 -C re -fl o x /fl o x

M o use

A w ake-Im m o b ility

1 m V

W alkin g

1

s e c

B

Awake-Im m obility

Walking

7 0

Frequency (Hz)

1 0 0

6 0

9 0

5 0

8 0

4 0

7 0
3 0

6 0

2 0

5 0

1 0

4 0
3 0

0

2 0

-1 0

1 0

-2 0

0

-3 0
1 0

0

2 0

3 0

4 0

5 0

6 0

0

1 0

T im e (s ec)

C

2 0

3 0

4 0

5 0

6 0

T im e (se c)

5

Power
(dB)

Immobile No Drug
Walking No Drug

Log Power

4

3
2

1
0
0

10

20

30

40

50

60

70

80

90

100

F re q u e n c y (H z )

Figure 5 Hippocamapl activation of a representative VAChTNkx2.1-Cre-flox/flox mouse. A)
LFP traces recorded from the CA1 region of the hippocampus of a HET mouse during
awake-immobility (top) and walking (bottom). B) Time-frequency spectrogram indicates
stable theta frequency during 60 sec of recording, and the higher gamma power during
walking than immobility C) Power spectra during awake-immobility (blue trace) and
walking (red trace). Theta rhythm during awake-immobility was lower in frequency and
amplitude as compared to the same measure recorded during walking. Power of gamma is
significantly higher during walking.
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Figure 6 Effects of behavior on hippocampal activation of WT (n = 6), HET (n = 6), and
KO (n = 6) mice. Values are expressed as mean ± SEM. * P<0.05, *** P<0.001:
difference between awake-immobility and walking using repeated measures two-way
ANOVA followed by Bonferroni test. In each group of mice, theta was higher in power
and peak frequency, and high-frequency gamma was higher during walking as compared
to the same measure during awake-immobility. In HET and KO mice, but not in WT
mice, low-frequency gamma was higher during walking than immobility.
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Figure 7 Comparison of hippocampal activation of WT (n = 6), HET (n = 6), and KO (n
= 6) mice. Values are expressed as mean ± SEM. * P<0.05, *** P<0.001: difference
between groups using repeated measures two-way ANOVA followed by Bonferroni test.
Awake-immobility: Theta peak frequency is significantly higher in WT mice as compared
to KO mice. Theta power decreases in the order of WT, HET and KO mice. No
significant group differences were observed for the power of low- or high-frequency
gamma rhythm. Walking: HET mice manifested significantly higher theta peak frequency
as compared to WT mice. Theta power did not differ significantly amongst the groups.
Low-frequency gamma power of KO mice during walking was significantly stronger than
WT mice.
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3.2 Injection of scopolamine hydrochloride
In order to evaluate the response of mutant mice to a cholinergic antagonist drug,
mice from all groups were injected with the muscarinic cholinergic antagonist
scopolamine hydrochloride (5 mg/kg i.p.). Ten minutes post injection, LFPs were
recorded for another 30 to 45 minutes. Results obtained from both mutant groups were
compared with the WT mice.

3.2.1 Wild-type mice
Scopolamine hydrochloride abolished the awake-immobility hippocampal theta
rhythm in WT mice (Fig. 8, 14). By contrast, during walking, scopolamine injection
resulted in a non-significant decrease of theta rhythm peak frequency (7.64 ± 0.32 Hz; n
= 6; P = 0.72; paired t-test; Fig 9, 15). However, power of theta was suppressed
significantly after injection of scopolamine (0.44 ± 0.04 log units; n = 6, P < 0.001;
paired t-test; Fig. 9, 15). A two-factor ANOVA (behavior x drug) followed by Bonferroni
test was performed to analyze the effects of scopolamine injection on hippocampal
gamma oscillations. No significant change was observed in power of low frequency
gamma after administration of scopolamine during both behaviors (n = 6, F (1, 10) = 1.77,
P = 0.21; Fig. 8-9, 14-15). Average logarithmic power of low gamma during awakeimmobility and walking were 2.41 ± 0.11 and 2.62 ± 0.24 log units respectively (Fig. 14,
15). High frequency gamma power (awake-immobility: 1.87 ± 0. 14 log units, walking:
2.03 ± 0.16 log units) also did not change significantly after injection of scopolamine (2way ANOVA, n = 6, F (1, 10) = 0.06, P = 0.81; Fig 8-9, 14-15).
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Figure 8 Effects of administration of scopolamine on hippocampal activation of a
representative wild-type mouse during awake-immobility. A) LFP traces (6 seconds)
before and after scopolamine injection. B) Time-frequency spectrogram and C) Power
spectra before (red trace) and after administration of scopolamine (blue trace).
Scopolamine injection abolished the theta peak during awake-immobility, but did not
change significantly the low- and high-frequency gamma power.
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Figure 9 Effects of administration of scopolamine on hippocampal activation of a
representative wild-type mouse during walking. A) LFP traces (6 seconds) before and
after scopolamine injection. B) Time-frequency spectrogram and C) Power spectra
representation of hippocampal activation of a WT mouse before and after administration
of scopolamine. Blue line corresponds to baseline while red line represents post
scopolamine. Theta power was decreased significantly after scopolamine injection, but its
peak frequency remained quite intact. Scopolamine injection did not significantly change
the power of either low or high frequency gamma.
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3.2.2 VAChT KDHET mice
Theta rhythm in HET mice was less sensitive to scopolamine as compared to theta
in WT mice. Scopolamine injection failed to abolish the awake-immobility theta rhythm
in HET mice; however, both peak frequency and power of theta were significantly
attenuated (Fig. 10). The lack of scopolamine sensitivity of awake-immobile theta rhythm
in the hippocampus of HET mice was different from WT mice (3.2.1). Theta peak
frequency was reduced from 4.92 ± 0.03 Hz to 3.49 ± 0.21 Hz (n = 6, P < 0.01; Fig. 14).
Scopolamine suppressed the power of theta rhythm during both immobility and walking
(awake-immobility: before scopolamine: 0.40 ± 0.02 log units, after scopolamine 0.17 ±
log units, n = 6, P < 0.001; walking: 0.37 ± 0.02 log units while baseline power was 0.89
± 0.04 log units, n = 6, P < 0.0001; Fig 14-15). Similar to WT mice, the walking theta
peak frequency was not changed significantly by scopolamine (7.96 ± 0.32 Hz, report
baseline again n = 6, P = 0.32; Fig. 15). As observed for the WT mice, injection of
scopolamine to HET mice also did not alter the power of low frequency gamma during
awake-immobility or walking (2-way repeated measures ANOVA, n = 6 mice, F (1, 10) =
1.33, P = 0.28; Fig. 10-11, 14-15). High frequency gamma power also did not change
significantly after scopolamine during awake-immobility (1.73 ± 0.12 log units) or during
walking (1.94 ± 0.12 log units; 2-way ANOVA, n = 6, 2-way repeated measures ANOVA
F (1, 10) = 0.05, P = 0.82; Fig. 10-11, 14-15).
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Figure 10 Effects of administration of scopolamine on hippocampal activation of a
representative VAChT KDHET mouse during awake-immobility. A) LFP traces (6
seconds) before and after scopolamine injection. B) Time-frequency spectrogram and C)
Power spectra before (red trace) and after administration of scopolamine (blue trace).
Scopolamine injection shifted the theta peak to a lower frequency and reduced its power.
Scopolamine did not change significantly the low- and high-frequency gamma power.
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Figure 11 Effects of administration of scopolamine on hippocampal activation of a
representative VAChT KDHET mouse during walking. A) LFP traces (6 seconds) before
and after scopolamine injection. B) Time-frequency spectrogram and C) Power spectra
representation of hippocampal activation of a HET mouse before and after administration
of scopolamine. Blue line corresponds to baseline while red line represents post
scopolamine. Although power of theta rhythm was significantly suppressed after
scopolamine injection, its peak frequency remained quite intact. Scopolamine injection
did not significantly change the power of either low- or high-frequency gamma.
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3.2.3 VAChTNkx2.1-Cre-flox/flox mice
Sensitivity of hippocampal LFPs to scopolamine was similar in KO and WT mice.
Theta generated during awake-immobility was abolished by scopolamine injection (Fig.
12). Walking-induced theta peak did not change significantly after administration of
scopolamine (7.79 ± 0.21 Hz, n = 6, P = 0.71, paired t-test; Fig. 13, 15). Unlike in WT
and HET mice, power of walking-induced theta was not suppressed significantly post
scopolamine injection (0.83 ± 0.08, n = 6, P = 0.21, paired t-test; Fig. 13, 15).
Scopolamine also failed to alter the power of low-frequency gamma generated during
awake-immobility (2.64 ± 0.13 log units; Fig. 14). A similar result was observed for the
walking-induced low-frequency gamma (2.93 ± 0.15 log units, n = 6, F (1, 10) = 0.19, P =
0.67; Fig. 15). High-frequency gamma during awake-immobility showed a nonsignificant increase of power after scopolamine (1.87 ± 0.12 log units, n = 6; Fig. 12, 14).
Scopolamine injection did not change the power of walking-induced high frequency
gamma (2.16 ± 0.13 log units, n = 6, F (1, 10) = 0.36, P = 0.56; Fig. 13, 15).
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Figure 12 Effects of administration of scopolamine on hippocampal activation of a
representative VAChTNkx2.1-Cre-flox/flox mouse during awake-immobility. A) LFP traces (6
seconds) before and after scopolamine injection. B) Time-frequency spectrogram and C)
Power spectra before (red trace) and after administration of scopolamine (blue trace).
Scopolamine injection abolished the theta peak during awake-immobility, but did not
change significantly the low- and high-frequency gamma power.
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Figure 13 Effects of administration of scopolamine on hippocampal activation of a
representative VAChTNkx2.1-Cre-flox/flox mouse during walking. A) LFP traces (6 seconds)
before and after scopolamine injection. B) Time-frequency spectrogram and C) Power
spectra representation of hippocampal activation of a KO mouse before and after
administration of scopolamine. Blue line corresponds to baseline while red line represents
post scopolamine. Injection of scopolamine failed to alter any of the four variables
significantly.
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Figure 14 Effect of scopolamine on hippocampal activation of WT (n = 6), HET (n = 6),
and KO (n = 6) mice during awake-immobility. Values are expressed as mean ± SEM. *
P<0.05, *** P<0.001: difference between no drug and scopolamine using repeated
measures two-way ANOVA followed by Bonferroni test. Scopolamine abolished theta
peak frequency and power in WT and KO mice, and attenuated theta frequency and
powerin HET mice. No significant change was noticed in power of gamma in any mouse
groups after scopolamine.

47

Theta Peak Frequency

Theta Rhythm Power
1.5
L ogar ithmic Pow er

10

Frequency (Hz)

8
6
4
2
0

HET Mice

WT Mice

HET Mice

0.5

KO Mice

KO Mice

High Frequency Gamma Rhythm Power

Low Frequency Gamma Rhythm Power

2.5

Logar it hmic Power

4

Logarithmic Power

***

1.0

0.0
WT Mice

***

3
2
1

2.0
1.5
1.0
0.5
0.0

0
WT Mice

HET Mice

KO Mice

WT Mice

HET Mice

KO Mice

Figure 15 Effect of scopolamine on hippocampal activation of WT (n = 6), HET (n = 6),
and KO (n = 6) mice during walking. Values are expressed as mean ± SEM. ***
P<0.001: difference between no drug and scopolamine using repeated measures two-way
ANOVA followed by Bonferroni test. Theta peak frequency did not change significantly.
Theta power attenuated in WT and HET mice but not in KO mice. Scopolamine failed to
alter the power of gamma oscillations in all three groups during walking.
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3.3 CPP injection
To investigate the source of compensation which might have happened in HET
mice, the NMDA receptor antagonist 3-[(R)-2-carboxypiperazin-4-yl]-prop-2-enyl-1phosphonic acid (CPP) was injected (10 mg/kg i.p.) to mice from all groups. The LFPs
were recorded from mice 30 minutes post injection.

3.3.1 Wild-type mice
CPP injection did not alter the awake-immobile theta peak frequency significantly
(3.98 ± 0.21 Hz, n = 6, P = 0.13); however, walking-induced theta peak frequency was
suppressed significantly (7.01 ± 0.30 Hz, n = 6, P < 0.05) as compared to baseline (7.83 ±
0.20 Hz). Power of theta was significantly suppressed during awake-immobility and
walking after injection of CPP (awake-immobility: 0.38 ± 0.04 log units, n = 6, P < 0.05;
walking: 0.24 ± 0.03 log units, n = 6, P < 0.001). No significant change was observed
post CPP injection in the power of low frequency gamma oscillations during either of the
behaviors (awake-immobility: 2.40 ± 0.1 log units; walking: 2.55 ± 0.09; 2-way
ANOVA, n = 6, F (1, 10) = 0.15, P = 0.70; Fig. 16-17, 22-23). There was a non-significant
increase in power of high frequency gamma during awake-immobility (1.86 ± 0.09 log
units; Figure 16, 22). Power of high frequency gamma after CPP injection during walking
was 2.09 ± 0.16 log units, which did not differ from baseline significantly (2-way
ANOVA, n = 6, F (1, 10) = 0.05, P = 0.84; Fig. 17, 23).
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Figure 16 CPP injection and hippocampal activation in a Wild-Type mouse during
awake-immobility. A) LFP traces (6 seconds) before and after CPP injection. B) Timefrequency spectrogram and C) Power spectra representation of hippocampal activation of
a WT mouse before and after administration of CPP. Blue line corresponds to baseline
while red line represents post CPP. Power of theta rhythm but not theta peak frequency
was suppressed significantly by CPP. CPP injection did not significantly change the
power of either low- or high-frequency gamma.

50

W ild -Ty p e M o u s e
A

W alkin g N o D ru g

1 m V

W alkin g C P P

1

s e c

B

No Drug

CPP

7 0

Frequency (Hz)

1 0 0

6 0

9 0

5 0

8 0
4 0

7 0

3 0

6 0

2 0

5 0

1 0

4 0
3 0

0

2 0

-1 0

1 0

-2 0

0

-3 0
0

1 0

2 0

3 0

4 0

5 0

6 0

0

1 0

Tim e (sec)

2 0

3 0

4 0

5 0

6 0

Tim e (sec)

Power
(dB)

C
5
Walking Control
Walking CPP

Log Power

4
3
2
1
0
0

10

20

30

40

50

60

70

80

90

100

F re q u e n c y (H z )

Figure 17 CPP injection and hippocampal activation in a Wild-Type mouse during
walking. A) LFP traces (6 seconds) before and after CPP injection. B) Time-frequency
spectrogram and C) Power spectra representation of hippocampal activation of a WT
mouse before and after administration of CPP. Blue line corresponds to baseline while
red line represents post CPP. CPP suppressed both power and peak frequency of theta
rhythm significantly, but it did not significantly change the power of either low- or highfrequency gamma.

51

3.3.2 VAChT KDHET mice
Administration of CPP abolished the awake-immobility theta rhythm. A theta
peak, as indicated by rise of the theta peak, was not detected in any of the six HET mice
during awake-immobility (Fig. 18). CPP shifted the walking-induced theta rhythm peak
to a significantly lower frequency (7.59 ± 0.28 Hz; n = 6, P < 0.05, paired t-test; Fig. 19,
22). Furthermore, power of theta recorded during walking was significantly attenuated
(3.53 ± 0.02 log units; n = 6, P < 0.0001, paired t-test; Fig. 19, 23). Similar to WT mice,
low-frequency gamma power in HET mice did not change significantly post CPP (awakeimmobility: 2.60 ± 0.15 log units; walking: 2.79 ± 0.08 log units; 2-way ANOVA, n = 6,
F (1, 10) = 0.40, P = 0.54; Fig. 18-19, 22-23). When compared to baseline recording, power
of high frequency gamma was not altered significantly post CPP injection (awakeimmobility: 1.96 ± 0.15 log units; walking: 2.11 ± 0.14 log units; 2-way repeated
measures ANOVA, n = 6, F (1, 10) = 0.61, P = 0.45; Fig. 18-19, 22-23).
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Figure 18 CPP injection and hippocampal activation in a VAChT KDHET mouse during
awake-immobility. A) LFP traces (6 seconds) before and after CPP injection. B) Timefrequency spectrogram and C) Power spectra before (blue trace) and after administration
of CPP (red trace). CPP injection abolished the theta peak during awake-immobility, but
did not change significantly the low- and high-frequency gamma power.
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Figure 19 CPP injection and hippocampal activation in a VAChT KDHET mouse during
walking. A) LFP traces (6 seconds) before and after CPP injection. B) Time-frequency
spectrogram and C) Power spectra before (blue trace) and after administration of CPP
(red trace). CPP injection significantly attenuated the power of theta. Theta peak shifted
to a lower frequency. CPP failed to change the low- and high-frequency gamma power.
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3.3 VAChTNkx2.1-Cre-flox/flox mice
CPP injection did not change the peak frequency of awake-immobility theta in the
KO (VAChTNkx2.1-Cre-flox/flox) mice (4.04 ± 0.19 Hz, n = 6, P = 0.43), but it significantly
reduced the walking theta frequency (6.91 ± 0.12 Hz, n = 6, P < 0.01). In contrast to WT
mice, CPP failed to alter the theta power during awake-immobility (0.069 ± 0.02 log
units, n = 6, P = 0.35). However, theta power during walking (0.29 ± 0.03 log units) was
suppressed significantly (n = 6, P < 0.0001). Average logarithmic power of lowfrequency gamma rhythm was 2.55 ± 0.12 log units during awake-immobility and 2.86 ±
0.12 log units while walking (Fig. 22-23). Similar to WT mice, power of both low- and
high-frequency gamma did not change significantly during awake-immobility or walking
in response to CPP injection.
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Figure 20 CPP injection and hippocampal activation in a VAChTNkx2.1-Cre-flox/flox mouse
during awake-immobility. A) LFP traces (6 seconds) before and after CPP injection. B)
Time-frequency spectrogram and C) Power spectra representation of hippocampal
activation of a KO mouse before and after administration of CPP. Blue line corresponds
to baseline while red line represents post CPP. Injection of CPP failed to alter any of the
four variables significantly.
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Figure 21 CPP injection and hippocampal activation in a VAChTNkx2.1-Cre-flox/flox mouse
during walking. A) LFP traces (6 seconds) before and after CPP injection. B) Timefrequency spectrogram and C) Power spectra before (blue trace) and after administration
of CPP (red trace). CPP injection significantly attenuated the power of theta. Theta peak
shifted to a lower frequency. CPP significantly suppressed the power of low-frequency
gamma power but not high-frequency gamma power.
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Figure 22 Effect of CPP on hippocampal activation of WT (n = 6), HET (n = 6), and KO
(n = 6) mice during awake-immobility. Values are expressed as mean ± SEM. * P<0.05,
*** P<0.001. Repeated measures two-way ANOVA (behavior x drug) followed by
Bonferroni test was used. WT Mice: Theta power attenuated while its peak frequency did
not change significantly. CPP injection failed to alter the power of gamma oscillations.
HET Mice: Immobile theta peak was not observed, thus zero theta power, and the power
of low- and high-frequency gamma was not significantly changed after CPP. KO Mice:
None of the four variables changed significantly after injection of CPP.
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Figure 23 Effect of CPP on hippocampal activation of WT (n = 6), HET (n = 6), and KO
(n = 6) mice during walking. Values are expressed as mean ± SEM. * P<0.05, ** P<0.01,
*** P<0.001. Repeated measures two-way ANOVA (behavior x drug) followed by
Bonferroni test was used. In all three groups of mice, theta power was strongly attenuated
after injection of CPP. Theta peak also shifted to a significantly lower frequency in all
groups. Although CPP suppresses the low-frequency gamma power in KO mice, no
significant reduction was noticed in WT and HET mice. Power of high-frequency gamma
did not vary significantly in any of the three groups after administration of CPP.
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4 Discussion
4.1 Hippocampal activation during awake-immobility
My results indicate that two types of theta rhythm are generated within the
hippocampus based on the behavior. This is consistent with previous findings
(Vanderwolf, 1969; Vanderwolf, 1975; Leung et al., 1982; Oddie and Bland, 1998; Bland
and Oddie, 2001). Theta rhythm generated during awake-immobility in all groups of mice
had significantly lower peak frequency and power as compared with the walking induced
theta. No significant difference was found in the power of either low- or high-frequency
gamma activity between groups during awake-immobility.
Vanderwolf (1988) suggested that different neurotransmitters regulate generation
of each type of theta rhythm. Multiple studies using cholinergic agonist and antagonist
drugs showed that acetylcholine (ACh) is the neurotransmitter responsible for generation
of hippocampal theta rhythm during awake-immobility (Sainsbury et al., 1987;
Vanderwolf, 1988; Leung 1998; Tai et al., 2011). I found that the power of theta during
awake-immobility decreased in the order of Wild-Type, VAChT KDHET and
VAChTNkx2.1-Cre-flox/flox, which is the order of expected availability of synaptically released
acetylcholine in the septohippocampal system This further suggests that cholinergic
functionality is necessary for generation of awake-immobility theta.
The awake-immobility theta is also referred to as atropine-sensitive. Injection of
scopolamine in all three groups of mice was accompanied by a short period (~5 minutes)
of hyperactivity followed by a longer period (~20 minutes) of immobility. My data
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showed that administration of scopolamine abolished the theta generated during awakeimmobility in Wild-Type and VAChTNkx2.1-Cre-flox/flox mice. Atropine-sensitive theta has
been suggested to indicate sensory processing in the hippocampus (Vanderwolf, 1988).
Based on this model the atropine-sensitive theta provides sensory information required
for the initiation of voluntary movement or signal the intensity of an upcoming
movement. This is consistent with the sensorimotor integration model proposed by Bland
and Oddie (2001).
Despite the fact that VAChT was deleted from basal forebrain of the
VAChTNkx2.1-Cre-flox/flox mice (Al-Onaizi, under review), a low power theta was still
present during awake-immobility. Two reasons could account for this result. First, some
ACh is still being released in the septo-hippocampal pathway in these forebrain-VAChT
knockout mice, despite near zero VAChT levels assessed by protein and mRNA (AlOnaizi, under review). Next, cholinergic neurons projecting from pedunculopontine
tegmental nucleus (PPT) to the medial septum (MS) play a role in generation of atropinesensitive theta. Direct application of atropine to the MS eliminated the atropine-sensitive
theta rhythm in the hippocampus in the rat under urethane anesthesia (Stewart and Fox,
1989),

which

may

block

muscarinic

cholinergic

synapses

on

GABAergic

septohippocampal neurons (Alreja et al., 2000; Wu et al., 2000). Stimulation of PPT or
infusion of cholinergic agonists into the PPT has been shown to induce hippocampal
theta (Vertes, 1982; Vertes et al., 1993).
Another interesting result was the failure of scopolamine injection in totally
abolishing the atropine-sensitive theta in VAChT KDHET mice. Administration of
scopolamine suppressed the theta power significantly and shifted the peak to a lower
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frequency but failed to abolish it. This suggests that a compensatory mechanism might
have developed in these mice. Based on the model proposed by Colom (2006),
septohippocampal cholinergic neurons, in addition to septohippocampal glutamaterigc
neurons, help to increase the level of excitation within the medial septum to a threshold
necessary for oscillation in theta frequency. It is possible that the septohippocampal
glutamatergic neurons release more glutamate in order to compensate for the cholinergic
deficiency.
In another study by Allen et al., (2006), cholinergic basal forebrain neurons (in
vitro) were shown to be capable of releasing glutamate as a co-transmitter. Co-release of
glutamate was subjected to the negative-feedback inhibition regulated by the M2 subtype
muscarinic cholinergic receptors located presynatically. Prado et al., 2006 reported that
release of ACh was reduced to ~33% in VAChT KDHET mice. In VAChT KDHET mice,
decreased release from basal forebrain cholinergic neurons may result in less feedback
inhibition through M2 receptors, and more glutamate being co-released.
Thus, I predict that, decreasing cholinergic tone may trigger the glutamatergic
neurons to increase their activity or enhance the release of glutamate from basal forebrain
cholinergic neurons. In agreement with this, NMDA receptor antagonist CPP abolished
the awake-immobility theta in VAChT KDHET mice, and not other groups of mice. In
contrast, immobility theta in wildtype and VAChTNkx2.1-Cre-flox/flox mice was not
significantly affected after CPP injection. Other than expecting to block glutamatergic
NMDA receptor-mediated synaptic transmission in the hippocampus, CPP is expected to
block NMDA receptors mediated by septo-hippocampal glutamatergic neurons synapsing
on both hippocampal and medial septal neurons, and glutamatergic neurons projecting
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from SUM directly to the hippocampus (Kiss et al., 2000) and indirectly to the medial
septum (Vertes, 1992; Borhegyi et al., 1998). The nature of compensation that may have
happened in these SUM, septohippocampal, or hippocampal glutamatergic neurons
remains to be studied.

4.2 Hippocampal activation during walking
Theta power during walking did not show a significant difference among the
different VAChT mutants, suggesting that the amplitude of walking-induced theta might
be mainly mediated by non-cholinergic neurons. GABAergic (Stewart and Fox, 1990;
Yoder and Pang, 2005; Simon et al., 2006, Borhegyi et al., 2006) and glutamatergic
(Leung and Desborough, 1988; Leung and Shen, 2004) septo-hippocampal inputs may
maintain the theta rhythmicity during voluntary movements. In addition to septohippocampal inputs, serotonin may mediate walking induced theta (Vanderwolf, 1988).
My study showed a decrease in walking-induced theta power following
scopolamine injection in Wild-Type and VAChT KDHET mice but not in VAChTNkx2.1-Creflox/flox

mice. This result supports the proposal that an atropine-sensitive component is also

found in the hippocampal theta rhythm during walking in the wildtype and VAChT
KDHET mice (Shin et al., 2005), similar to rats (Vanderwolf, 1988; Leung, 1998; Bland
and Oddie, 2001). In a study by Leung (1985), the rise of the theta peak recorded during
walking was reduced after atropine. On the other hand, the lack of atropine sensitivity of
the walking theta in VAChTNkx2.1-Cre-flox/flox mice may be expected for mice without
acetylcholine release in the septohippocampal neurons, and brainstem cholinergic inputs
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to the medial septum were apparently not participating in atropine sensitivity during
walking.
Power of theta rhythm during walking was suppressed in all groups of mice after
injection of CPP, suggesting that glutamate and NMDA receptors have a critical role in
the generation of walking induced theta. Injection of NMDA receptor antagonist D-2amino-5-phosphonovaleric acid (D-APV) directly to the medial septum suppressed the
amplitude of theta significantly (Leung and Shen, 2004). No such reduction was noticed
by injection of AMPA receptors antagonist (DNQX) suggesting postsynaptic NMDA
receptors in the medial septum control the amplitude of the hippocampal theta rhythm
(Leung and Shen, 2004). Other than medial septum, theta recorded in CA1 is partially
driven by distal-dendritic excitation of the pyramidal cells by the perforant pathway from
the entorhinal cortex (Vanderwolf and Leung, 1983; Leung, 1984). This pathway is
mediated by both NMDA and AMPA receptors (Colbert and Levy, 1992) and
inactivation of this pathway strongly attenuated theta rhythm (Heynan and Bilkey, 1994).
Furthermore, the independent pacemaker in the CA3 (Kocsis et al., 1999), activated by
septohippocampal cholinergic neurons, also have a role in generation of theta in CA1
region. APV blocked the theta rhythm induced by cholinergic agonists in CA3 in vitro
(Fellous and Sejnowski, 2000).
There may be several reasons why atropine-resistant theta was not totally
abolished after CPP injection. First, cholinergic, atropine-sensitive component also drives
or facilitates theta during walking (Vanderwolf, 1988; Leung, 1998; Bland and Oddie,
2001). Second, only the NMDA component of normal glutamatergic transmission is
blocked, and the non-NMDA component remains intact. In addition, glutamate may only
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be one of the more important neurotransmitter mediating the atropine-resistant theta, and
other neurotransmitters such as GABA and serotonin may also play a role in generation
of the theta rhythm during walking. The medial septum projects GABAergic neurons to
the hippocampus. GABA released from these neurons attaches to the GABA-A receptors
located postsynaptically on the interneurons. Medial septal injection of muscimol, a
GABA-A receptor agonist also attenuated the hippocampal theta amplitude (Bland et al.,
1996). Serotonin depletion via selective lesion of median raphe neurons or sectioning of
presumed 5-HT pathway to the hippocampus strongly attenuated the power of walking
induced theta (Vanderwolf, 1988).
In all three groups of mice studied here, the peak of the theta rhythm shifted to a
significantly lower frequency after injection of CPP, while no such effect was observed
after administration of scopolamine. Kirk (1998) suggested that the frequency of the theta
rhythm is coded downstream to the medial septum, presumably in the SUM. MS-DBB
receives phasic information from SUM, the frequency of which determines the frequency
of septal bursting and that of hippocampal theta (Kirk, 1998). SUM acts as the
intensity/frequency transducer (Kirk, 1998). SUM receives many inputs from the
brainstem that are glutamatergic (Kiss et al., 2002). The reduction of theta frequency after
CPP might be due to the fact that the NMDA component of these glutamatergic pathways
has been disrupted. Theta peak frequency of VAChT KDHET mice was significantly
higher than Wild-Type and VAChTNkx2.1-Cre-flox/flox mice which might have resulted from
higher glutamatergic release in the SUM or medial septum, as a consequence of low
cholinergic presynaptic inhibition (Allen et al., 2006), or as a consequence of
compensation during development.
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Administration of CPP severely impaired voluntary movement in all three groups,
as has been observed after other NMDA receptor antagonists (Leung and Shen, 2004).
Mice showed difficulty maintaining balance, moving hind limbs, standing and jumping.
These symptoms started to appear almost 45 minutes post injection and they recovered a
few hours later. Walking data included in the analysis of my results in the thesis were all
recorded before the onset of these symptoms.

4.3 Gamma oscillations
Gamma activity is proposed to be generated by a recurrent inhibition circuit
involving pyramidal cells and GABAergic interneurons (Leung, 1982, 1998; Mann et al.,
2005), and brainstem input is suggested to increase recurrent inhibitory gain and increase
gamma oscillations (Leung, 1982). Power of gamma increased during walking as
compared to immobility in mice. The increase of low-frequency (30-70 Hz) gamma
power was significant in the two mutant mouse lines but not in Wild-Type mice. Highfrequency (70-100 Hz) gamma power increased significantly in all three groups during
walking. Stumpf (1965b) showed that 0.75 mg/kg (they did not say i.p. or i.v., but it is
common to inject rabbits i.v.) scopolamine did not prevent the evocation of hippocampal
gamma activity evoked by brainstem stimulation in immobilized unanesthetized rabbits.
In contrast to Stumpf, Leung (1985) reported that atropine caused a decrease in gamma
activity in rats. My results indicated that scopolamine failed to change the power of
gamma oscillations significantly. This observation was consistent for all three groups of
mice both during walking and awake-immobility. My results showed that injection of the
NMDA receptor glutamatergic antagonist CPP, failed to change the power of low- and
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high-frequency gamma oscillation during awake-immobility and walking with the
exception of power of low-frequency gamma of VAChTNkx2.1-Cre-flox/flox mice during
walking. This is consistent with the finding that AMPA receptor, but not NMDA
blockade, in the hippocampus attenuated hippocampal gamma rhythm (Leung and Shen,
2004).

4.4 Limitations and future studies
While electrophysiology of the hippocampus of these two mutant mouse lines was
studied during walking and awake-immobility, I did not study the hippocampal activation
of these mice during sleep. LFPs recorded in this study were limited to the CA1 region of
the hippocampus while it is important to record LFPs from other brain regions such as the
neocortex. Efforts were made to select the best LFPs for each type of behavior; however,
simultaneous video-LFP recording will significantly reduce the chance of errors made in
this selection. Another major limitation in my study was proper placement of the
electrodes as brain size varies from mouse to mouse. Using multi-channel electrodes will
significantly increase the chance of placing electrodes into specific layer of the
hippocampus, as well as provide laminar profiles of the LFPs. Cholinesterase inhibitor
drugs such as galantamine are among the most common types of drugs used in
controlling patients with AD. Since VAChT and acetylcholine deficient mice are models
for AD, it is important to study the effects of these drugs on LFPs and behavior.
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4.5 Conclusion
The availability of VAChT KDHET and VAChTNkx2.1-Cre-flox/flox mutant mouse lines
displaying different levels of VAChT expression provides us with the unique opportunity
to evaluate the consequences of reduced VAChT levels for brain functions. Multiple
behavioral deficits such as social and object recognition, spatial memory, attention in the
5 choice serial reaction task and hyperactivity were observed in these genetically
modified mice (Prado et al., 2006; Martin-Silva et al., 2011; Martyn et al., 2012: AlOnaizi et al., under review). The primary goal of this study was to use electrophysiology
to record LFPs from the hippocampus of these two mutant mouse lines in order to further
define the role of VAChT and ACh release on hippocampal activation during awakeimmobility and walking. The main findings of the present experiments are that (1)
VAChT expression and ACh release are necessary for generation of hippocampal theta
rhythm during awake-immobility, (2) generation of hippocampal theta rhythm during
walking involved non-cholinergic neurotransmitters., although ACh was also involved
(Leung, 1998); (3) gamma power in the hippocampus of VAChT KDHET and
VAChTNkx2.1-Cre-flox/flox mice was not significantly different from that in Wild-Type mice,
suggesting cholinergic neurons have little impact on generation of hippocampal gamma
oscillations; (4) immobile theta in VAChTNkx2.1-Cre-flox/flox and Wild-Type mice was
sensitive to scopolamine, while VAChT KDHET mice was not. Furthermore, VAChT
KDHET mice, as compared to Wild-Type mice, manifested higher peak theta frequency
during walking. Cholinergic afferents from brainstem to septum may be compensated by
non-cholinergic brainstem-septal synapses in VAChT KDHET mice.
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